About

Trevena, Inc. is a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines.

GPCRs are the targets for at least one-third of modern medicinal products, and they remain the predominant class of targets under clinical evaluation. Trevena's expertise lies in understanding which signaling pathways downstream of a GPCR are associated with beneficial versus adverse biological effects, and in engineering "biased ligands" that activate only the beneficial pathways to unlock new biology and avoid drug adverse effects. Trevena's platform can be broadly applied across therapeutic areas and its pipeline currently includes programs in cardiovascular and CNS diseases.

Contact Info

1018 West 8th Avenue, Suite A, King of Prussia, PA, 19406
Tel: 610-354-8840
www.trevenainc.com

Polaris Lead

Terry McGuire

Social Media